New IBD drug candidate PVT401 enters first human safety trial
NCT ID NCT07423000
First seen Feb 25, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This early-stage study tests the safety of a new drug called PVT401 in 36 healthy volunteers. The drug is being developed for inflammatory bowel disease (IBD). Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to gather safety information before testing in patients with IBD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Pty Ltd
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.